Skip to content
AnalystLens

Omega Healthcare Investors 8-K Report, Financial Results (Jul 31, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 31, 2025
Period End
July 31, 2025
Security
OHI
In the record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.

Omega Healthcare Investors, Inc. (NYSE: OHI) reported second-quarter 2025 results on July 31, 2025, with net income of $140 milliona, or $0.46 per common share, compared with $117 million, or $0.45 per share, in Q2 2024.

Adjusted FFO was $232 millionb, or $0.77 per common share, on 303 million weighted-average diluted shares, compared with $185 million, or $0.71 per share, a year earlier. The company completed about $527 million of new investments in the quarter, including $502 million of real estate acquisitions, and issued $600 million of 5.2% senior unsecured notes due 2030. It also raised its 2025 AFFO guidance to $3.04 to $3.07 per diluted share, up from $2.95 to $3.01.

The filing highlights the status of several operators. LaVie completed its bankruptcy effective June 1, 2025, and its master lease was assigned to Avardis, with the monthly rent unchanged at $3.1 millionc and Avardis recognizing rental income on a straight-line basis of $3.6 million per month. Genesis Healthcare filed for Chapter 11 on July 9, 2025.

Omega agreed to provide an $8.0 milliond debtor-in-possession financing, which requires Genesis to pay full contractual rent, and the company expects to continue recognizing full rental and interest income from Genesis during the bankruptcy. The company also disclosed a $15.5 million non-cash straight-line receivable write-off tied to an operator moved to cash-basis revenue recognition after a going-concern doubt was raised. Balance sheet activity included total indebtedness of $5.0 billion at a weighted-average annual interest rate of 4.6% as of June 30, 2025, and cash and cash equivalents of $734.2 million.

Omega declared a quarterly dividend of $0.67 per share payable August 15, 2025. Management described the backdrop as highly favorable, citing improving operating metrics, an active pipeline and a cost of capital that supports continued accretive investment.

Key Highlights

  1. Q2 2025 net income of $140 million ($0.46 per share) versus $117 million ($0.45 per share) in Q2 2024; Adjusted FFO of $232 million ($0.77 per share) versus $185 million ($0.71 per share).
  2. Raised 2025 AFFO guidance to $3.04 to $3.07 per diluted share, from $2.95 to $3.01, including $605 million of new real property and loan investments completed year-to-date through June 2025.
  3. Completed approximately $527 million of Q2 investments, including 57 facilities acquired for $502.1 million (including a $344.2 million U.K. portfolio of 45 facilities) and $24.8 million of real estate loans at a 10.0% weighted average interest rate.
  4. Issued $600 million of 5.2% senior unsecured notes maturing in 2030 and extended the $1.45 billion revolving credit facility to October 30, 2025 and the $428.5 million term loan to August 8, 2026.
  5. Genesis Healthcare filed for Chapter 11 on July 9, 2025; Omega provided an $8.0 million DIP financing, and Genesis is required to pay full contractual rent during the process, which the company expects to continue recognizing in full.
  6. LaVie's lease was assigned to Avardis after LaVie's bankruptcy concluded June 1, 2025; Avardis paid full contractual rent of $3.1 million in July 2025 and is recognizing $3.6 million per month on a straight-line basis.
  7. Q2 2025 asset sales of $62.1 million generated a $22.9 million gain, offset by a $14.2 million net impairment on three facilities; quarterly dividend of $0.67 per share declared for payment August 15, 2025.

Frequently Asked Questions

  1. How did Omega perform in the second quarter of 2025?

    Net income was $140 million, or $0.46 per common share, versus $117 million, or $0.45 per share, in Q2 2024. Adjusted FFO was $232 million, or $0.77 per common share, on 303 million weighted-average diluted shares, compared with $185 million, or $0.71 per share, a year earlier. Funds Available for Distribution was $223 million, or $0.74 per share, versus $177 million, or $0.68 per share.

  2. What changed in the company's 2025 guidance?

    Omega increased its 2025 AFFO guidance to between $3.04 and $3.07 per diluted share, up from the prior range of $2.95 to $3.01. The revised guidance includes $605 million of investments completed year-to-date, assumes quarterly G&A of approximately $13.5 million to $14.5 million, and assumes the repayment of $600 million of 5.250% notes due January 2026 on October 15, 2025. It also assumes Genesis and Avardis continue paying full contractual obligations and that Maplewood continues paying $6.1 million per month in rent.

  3. What is the exposure to Genesis Healthcare's bankruptcy?

    Genesis filed for Chapter 11 on July 9, 2025. Omega agreed to provide an $8.0 million debtor-in-possession financing, and as a condition Genesis must pay full contractual rent during the bankruptcy. Interest on the DIP financing and existing term loans can be primarily paid-in-kind. In Q2 2025, Omega recorded $12.8 million of rental income and $4.1 million of interest income from Genesis, of which $2.5 million was PIK interest. Omega anticipates it will continue to recognize full rental and interest income during the bankruptcy.

  4. How is the company funding its growth and managing its debt?

    Omega issued 7 million common shares in Q2 for gross proceeds of $258 million, and its dividend reinvestment and ATM programs raised $250.2 million and $272.3 million, respectively, year-to-date through June 30, 2025. It issued $600 million of 5.2% senior notes due 2030 at 99.118% of face value. Total indebtedness was $5.0 billion at a weighted-average annual interest rate of 4.6%, with $734.2 million of cash and $1.45 billion of undrawn revolver capacity as of June 30, 2025.

  5. What is the dividend and when is it payable?

    On July 25, 2025, the Board declared a quarterly cash dividend of $0.67 per share, payable August 15, 2025, to common stockholders of record as of the close of business on August 4, 2025. Dividends declared were $0.67 per share in both Q2 2025 and Q2 2024.